X

Trial Profile

A PHASE I, OPEN-LABEL, NON-RANDOMIZED, DOSE-ESCALATING, SAFETY, TOLERABILITY, PHARMACOKINETIC, AND EFFICACY STUDY OF TAS-117 IN PATIENTS WITH ADVANCED SOLID TUMORS

Status: Recruiting

Phase of Trial: Phase I

Latest Information Update: 07 Dec 2021

Price : $35 ^*

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Pifusertib (Primary)
Indications Carcinoma; Endometrial cancer; Ovarian cancer; Solid tumours
Focus Adverse reactions; First in man
Sponsors Taiho Pharmaceutical

Most Recent Events

03 Aug 2018 Planned End Date changed from 31 Dec 2018 to 31 Dec 2019.
03 Aug 2017 Planned number of patients changed from 128 to 168.
03 Aug 2017 Planned End Date changed from 31 Dec 2017 to 31 Dec 2018.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com